SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
Scienture Holdings (NASDAQ: SCNX) said the U.S. Patent and Trademark Office granted U.S. Patent No. 12,622,903 B2 covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026 and expiring Feb. 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva. Scienture’s subsidiary has exclusive U.S. commercialization rights; REZENOPY™ was FDA-approved April 19, 2024. IQVIA data cited: ~$141M annual U.S. naloxone sales and 9.4M units (MAT Jan 2026).
How this was made
The 30-second read
Why it matters
The USPTO granted a patent covering REZENOPY 10 mg nasal spray through 2041, strengthening IP protection as SCNX moves toward a planned mid-July commercialization.
Market read
A long-dated US patent grant supports product defensibility and may improve investor confidence ahead of the cited mid-July launch.
What to watch
Key overhangs remain execution risks (commercial launch timing, payer coverage, inventory build) and dependence on Summit manufacturing and supply obligations.
Background
SCIENTURE Holdings’ subsidiary entered an agreement with Summit Biosciences for exclusive US commercialization rights to REZENOPY, approved by the FDA in April 2024.
Ticker impact
Scienture (SCNX) announced a USPTO patent grant covering REZENOPY naloxone nasal spray through 2041, supporting its planned mid-July commercialization.
Near-term positive bias for SCNX sentiment; magnitude likely limited without new financial guidance or launch metrics.
The news is company-specific (SCNX) and time-relevant (effective May 12, 2026; launch cited mid-July), but it is an IP milestone without quantified revenue impact or updated guidance in the article.
Market effects
Reinforces competitive differentiation in naloxone nasal spray via higher-dose differentiation and long-dated IP, potentially affecting perceived pricing power in the category.
Primarily US-focused (USPTO grant; US commercialization rights), with limited direct international read-through.
Modest global relevance unless similar IP/launch strategies are replicated outside the US.
Counterpoint
Patent issuance may already be priced in for a small-cap pharma; without updated sales forecasts, it may not translate into near-term earnings power.
Key entities
- public_companySCIENTURE HOLDINGS, INC.
NASDAQ-listed holding company; subject of the press release announcing the patent grant and commercialization plan.
- productREZENOPY™ (naloxone HCl) Nasal Spray 10 mg
FDA-approved naloxone nasal spray for emergency treatment of known or suspected opioid overdose; patent covers the product through 2041.
- subsidiarySummit Biosciences Inc.
Manufactures and commercially supplies REZENOPY under the March 2025 commercialization agreement; patent issued to Summit.
